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Abstract
Objective: to evaluate the acceptance and tolerability
of the nH1n1 2009 vaccine in HIv-positive individu-
als.
Method: 758 patients were included in this prospective
study. different study populations were formed: the
tolerability Study group consists of HIv-infected pa-
tients  who  visited  three  outpatient  clinics  (cologne,
Bonn, Freiburg) during a predefined time period. Pa-
tients were offered nH1n1 vaccination. those accept-
ing were administered a standard dose AS03 adjuvant
nH1n1 vaccine. Questionnaires to report side effects
occurring within 7 days after immunization were hand-
ed out.
In a substudy conducted during the same time peri-
od,  acceptance  towards  immunization  was  recorded.
this Acceptance Study group consists of all HIv-in-
fected patients visiting the cologne clinic . they were
offered vaccination. In case of refusal, motivation was
recorded.
Results: In the tolerability Study group, a total of 475
patient  diaries  returned  in  the  three  study  centres
could be evaluated, 119 of those (25%) reported no
side effects. distribution of symptoms was as follows:
Pain 285/475 patients (60%), swelling 96 (20%), red-
ness 54 (11%), fever 48/475 (10%), muscle/joint ache
173  (36%),  headache  127  (27%),  and  fatigue  210
(44%).  Association  of  side  effects  with  clinical  data
was calculated for patients in cologne and Bonn. Inci-
dence of side effects was significantly associated with
cdc stages A, B compared to c, and with a detectable
viral load (>50 copies/ml). no correlation was noted
for cd4 cell count, age, gender or ethnicity.
In the Acceptance Study group, 538 HIv-infected
patients were offered vaccination, 402 (75%) accepted,
while 136 (25%) rejected. Main reasons for rejection
were: negative media coverage (35%), indecisiveness
with preference to wait until a later date (23%), in-
fluenza not seen as personal threat (19%) and scepti-
cism towards immunization in general (10%). 
Conclusion: A total of 622 HIv-infected patients were
vaccinated against nH1n1-influenza in the three study
centres. no severe adverse events were reported. the
tolerability was in most parts comparable to general
population. Acceptance rate towards influenza vacci-
nation was high (75%). those refusing the immuniza-
tion mentioned negative media coverage as the major
influence on their decision.
Key words: nH1n1, influenza, HIv, vaccine, tolerabili-
ty, adverse events, safety, acceptance
IntRoductIon
A novel swine-origin influenza A (H1n1) virus strain
was first described in April 2009 in Mexico and the
uSA  [1].  It  rapidly  spread  worldwide  and  caused  a
large number of infections and deaths. In germany,
the  first  cases  were  identified  in  April  [2],  numbers
rose to more than 15.000 documented cases until the
end of August [3] and the first attributable death in
germany occurred in September 2009 [4].
the  WHo  declared  a  pandemic  in  June  2009,
which, in germany, led to the implementation of a
pre-existing  pandemia  emergency  plan  (http://www.
rki.de/cln_160/nn_1960682/dE/content/InfAZ/I/
Influenza/Influenzapandemieplan.html;  last  accessed
September 20, 2010). Among other recommendations
and guidelines, this plan recommended active immu-
nization as the most effective approach to reduce ill-
ness and death from pandemic influenza based on a
risk-benefit analysis. In September 2009, the European
commission licensed two adjuvant vaccines, of which
the  monovalent  AS03  adjuvant  vaccine  Pandemrixﾮ
was used in germany [5]. Pandemrixﾮ contains inacti-
vated, split influenza virus with antigen equivalent to
A/california/7/2009 (H1n1)v-like strain (X-179A).
on october 2nd 2009, the Federal german vacci-
nation committee (StIKo) issued a common recom-
mendation for the immunization with Pandemrixﾮ, in
particular for people aged 6 years and older with in-
creased health risks as consequence of an underlying
chronic  disease  [6].  these  recommendations  include
patients with HIv infection.
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cations and critical course of disease regarding season-
al  influenza  [7-9].  It  has  been  shown  that  influenza
vaccination is safe, and only rarely influences viral load
and cd4 cell count. changes of these parameters ap-
peared to be transient and no effect on the progress of
the HIv infection could be seen [10]. Effectiveness of
an immunization against seasonal influenza has been
demonstrated in several studies [11]. thus annual vac-
cination against seasonal influenza in HIv patients is
part of standard recommendation in germany [12].
the aim of this study was to show the acceptance
and tolerability towards the active immunization with
Pandemrixﾮ in a cohort of HIv infected out-patients.
MEtHodS
In  this  prospective  multicenter  study,  all  patients  in
cologne, Bonn and Freiburg vaccinated with Pandem-
rixﾮ who returned their patient questionnaire were in-
cluded in the tolerability Study group. In a substudy
in cologne, acceptance of vaccination was investigat-
ed  among  all  HIv-infected  patients  eligible  for  in-
fluenza vaccination seen during the same time period
in  cologne  (Acceptance  Study  group).  cologne  pa-
tients who were immunized and returned their ques-
tionnaire were included in both study groups (Fig. 1).
this study was approved by local ethics committees.
tolERABIlIty
the tolerability Study group consists of all HIv-in-
fected patients who were vaccinated with Pandemrixﾮ
from  2nd november  to  23rd december  2009  in  the
three institutions mentioned above. Additionally, these
patients were given a patient diary to be used to record
symptoms, including their duration and severity over a
period  of  7  days  after  vaccination.  the  symptoms
were grouped into both local at the injection site such
as pain, redness, and swelling, and systemic symptoms
such as fever (above 38.0ﾰc), muscle and joint pain,
headache and fatigue. If no symptoms occurred, the
diary was to be left blank but handed in nonetheless.
the classification of severity used is based on the
common  toxicity  criteria  for  Adverse  Events  (ct-
cAE) v4.0, ranging from 1 (mild) over 2 (moderate)
and 3 (severe) to 4 (life threatening) (http://evs.nci.
nih.gov/ftp1/ctcAE/Archive/ctcAE_4.01_2009-
07-14_QuickReference_5x7.pdf; last accessed Septem-
ber 20, 2010). the diameter of local swelling and red-
ness was to be reported in millimetres. Patients were
asked to return the diary in a provided, pre-stamped
envelope.
AccEPtAncE
the Acceptance Study group comprises all HIv-in-
fected  patients,  who  were  treated  at  the  outpatient
ward in cologne during the same time period and did
not meet any of the exclusion criteria for vaccination.
All patients were informed about novel influenza and
the risks and benefits of active immunization. those
who rejected vaccination were interviewed regarding
their motives for rejection. they could choose among
the following set of answers: 1) advise against immu-
nization by family doctor; 2) scepticism towards vacci-
nation in general; 3) negative media coverage; 4) previ-
ous  reactions  to  vaccination  in  family  members  or
friends; 5) novel influenza not considered as a person-
al threat; 6) adverse events in the past; 7) preference to
wait until a later date to get vaccinated.
vAccInAtIon
Exclusion criteria for vaccination with Pandemrixﾮ in-
cluded: current fever; previous intolerance or allergies
to egg protein or components of the vaccine; previous
intolerance to vaccinations in general; first trimester
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Fig. 1. Profile of participants in this study.
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vaccination against the pandemic H1n1 influenza at
another institution.
those eligible were administered the standard dose
of  Pandemrixﾮ into  the  deltoid  muscle.  It  contained
3.75  ʼg  hemagglutinin  of  inactivated,  propagated  in
eggs,  split  influenza  virus  (A/california/7/2009
(H1n1)-like strain (X-179A)). the antigen production
equals that of the seasonal vaccine Influsplitﾮ (glaxo
Smith Kline, dresden, germany). the AS03 adjuvant
consists  of  squalene  (10.69  mg),  dl-ʱ-tocopherol
(11.86 mg) and polysorbate 80 (4.86 mg). Furthermore,
a standard dose contains 5 g thiomersal as preservative.
StAtIStIcAl AnAlySIS
nominal values were compared using the [chi]2 test.
Statistical  analyses  were  performed  using  Microsoft
Excel  2008  for  Mac,  (Microsoft  corp.,  Redmond,
Washington,  uSA)  and  SPSS,  release  17  (SPSS  Inc.,
chicago, Illinois, uSA).
RESultS
the demographic and HIv-related parameters for the
two study groups listed in table 1.
tolERABIlIty
the tolerability Study group comprises 475 patients
who  returned  their  questionnaire  in  the  three  study
centres,  255  in  cologne,  175  in  Bonn  and  45  in
Freiburg.
no symptoms at all were reported by 119 of 475
(25%)  patients.  77  (16%)  reported  local  symptoms
only, 55 (12%) systemic symptoms only and 224 (47%)
developed both local and systemic symptoms (table 2).
Analysis of association of symptoms with clinical
data was performed on patients in cologne and Bonn.
Patients from Freiburg could not be included, since
the informed consent in Freiburg did not cover this
analysis. those developing any symptoms were more
likely to have cdc stages A and B (248/318, 78%)
than stage c (73/107 cases, 68%; P = 0.042) and were
also more likely to have a detectable viral load greater
than 50 HIv-1 RnA copies/ml (79/95, (83%)) com-
pared to 142/202 (70%) patients with undetectable vi-
ral load (P = 0.018). no statistically significant associa-
tion  was  found  between  the  presence  of  symptoms
and age, gender, ethnicity or cd4 cell count.
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Table 1. demographic and HIv-related parameters.
tolerability Study group  HIv infected patients vaccinated
against pandemicinfluenzain the
two centres who returned their
patient’s diary
Acceptance Study group  HIvinfectedpatients,eligible for
active immunization, whovisited
the cologne outpatient clinic in
the predefined time period 
Sd Standard deviation
ARt Antiretroviral therapy
tolerability  Acceptance 
Study group Study group
n (total) 475 538
Male:Female 387:88 447:91
Mean age, years (Sd) 45 (ﾱ9) 45 (ﾱ9)
caucasian, n (%) 404 (85%) 453 (84%)
Mean absolute cd4-cells/ 498 (ﾱ194) 483 (ﾱ177)
ʼl (Sd)
HIv-RnA<50 copies/ 336 (77%) 393 (73%)
ml, n (%)
ARt treatment, n (%) 412 (87%) 462 (86%)
Table 2. Reported side effects (total number = 475) 
occurrence Mean duration Mean severity grade of Severity
1234
n (%) days (Sd) (*)  n (%) n (%) n (%) n (%)
local symptoms
Pain 285 (60%) 2.9 (ﾱ 1,1) 1.4 (ﾱ 0.5) 200 (42%) 69 (15%) 16 (3%) 0 (0%)
Swelling 95 (20%) 2.6 (ﾱ 1.3) 14.8 (ﾱ 17.1) † DDDD
Redness 52 (11%) 3.1 (ﾱ 1.5) 14.8 (ﾱ 17.1) † DDDD
Systemic symptoms 
Fever 47 (10%) 2.0 (ﾱ 1.0) 1.2 (ﾱ 0.3) 41 (9%) 6 (1%) 1 (0%) 0 (0%)
Muscle/jointache 172 (36%) 2.7 (ﾱ 1.3) 1.4 (ﾱ 0.5) 121 (25%) 38(8%) 14 (3%) 0 (0%)
Headache 126 (27%) 2.5 (ﾱ 1.5) 1.4 (ﾱ 0.6) 93 (20%) 21 (4%) 13 (3%) 0 (0%)
Fatigue 207 (44%) 2.8 (ﾱ 1.5) 1.5 (ﾱ 0.6) 125 (26%) 65 (14%) 20(4%) 0 (0%)
Sd Standard deviation
(*) Severity:  from  1  (mild)  to  4  (life  threatening),  according  to  ctcAE  v4.0  criteria  (except  severity  of  “swelling”  and 
“redness”, see below) 
† Severity of “swelling” and “redness”: mean diameter (standard deviation) in millimeters
D no grading system was used
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In the same time period, a total of 588 HIv-infected
patients  visited  the  outpatient  clinic  in  cologne,  of
which 50 (9%) were excluded from vaccination. Rea-
sons for exclusion were: Forty-one out of 588 (7%)
had  previously  been  vaccinated  against  nH1n1  in-
fluenza at a different institution and 9 out of 588 (2%)
met  a  medical  contraindication  (5  patients  suffered
from acute febrile infection and 4 were pregnant in the
first trimester).
Hence the Acceptance Study group consists of 538
patients, of which 402/538 (75%) agreed to being vac-
cinated, whereas 136 out of 538 (25%) refused vacci-
nation. Reasons for rejection are shown in Figure 2. 
no  significant  differences  were  noted  between
those accepting or refusing vaccination regarding age,
gender, ethnicity, cd4 count, viral load or cdc stage. 
In the Acceptance Study group, 255 out of 402 pa-
tients (63%) returned their diary and are therefore part
of the tolerability Study group as well, while 147 did
not return it (37%). those having returned the ques-
tionnaires  were  significantly  more  likely  to  have  a
cd4-cell count above 200 cells/ʼl (243/255 (95%)
vs. 129/147 (88%); P = 0.006). Additionally, they were
more likely to be within cdc stage A or B vs. cdc
stage c (181/255 (71%) vs 90/147 (61%); P = 0.044).
no significant association considering viral load, eth-
nicity, age or gender was found. 
dIScuSSIon
Among the HIv-infected patients in the Acceptance
Study group, vaccination with Pandemrixﾮ reached an
acceptance rate of 75%. this shows that very high im-
munization rates can be achieved in selected popula-
tions. In contrast, the average 2009 pandemic vaccine
coverage in the german population is between 6.8%
and 8% [13, 14]. this discrepancy might primarily be
caused  by  the  high  frequency  of  doctor-patient  en-
counters  within  the  HIv-treatment  setting,  allowing
patients to gather medical information about the bene-
fits of influenza vaccination easily.  Secondly, a good
level of self-education of HIv-patients about health-
related subjects can often be found, which might lead
to positive health-seeking behaviour.  
For the general population in germany, it has been
shown that media, such as television, radio and print,
were the major source of information regarding the
nH1n1  pandemic.  Fifty-five  percent  of  those  ques-
tioned  in  a  german  telephone  survey  reported  that
they felt insecure about influenza vaccination because
of conflicting media reports[15]. In our cohort, this is
reflected by the fact that negative media coverage fol-
lowed by indecisiveness were the main reasons of re-
jection of vaccination. 
of  the  402  distributed  patient  questionnaires  in
cologne,  255  were  handed  back  (63%).  the  patient
groups returning the diaries versus those failing to do
so did not differ regarding viral load, age, gender or
ethnicity. However, those not having returned it were
significantly more likely to have a cd4-cell count below
200/ﾵl  and/or  be  categorized  into  cdc  stage  c.
Among the reasons for failing to send back the diary
might be a general lack of compliance in those patients
which could in turn be among the reasons responsible
for having achieved advanced disease stages. It could
also be related to the reduced state of mental and phys-
ical health of those patients leading to limited mobility
and failure to comply with study requirements, i.e. to
complete and return the questionnaires in due time. 
Information on adverse events of the 402 patients
vaccinated in cologne was not only collected by evalua-
tion of patient questionnaires, but also by information
obtained in regular patient visits. this results in the to-
tal  number  of  622  patients  with  no  severe  adverse
events after the vaccination in all three study centres.
data on the tolerability of the vaccine in healthy
adults are available from a phase III study conducted
by gSK Biologicals, the manufacturer of Pandemrixﾮ
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Fig. 2. Reasons to reject the vaccination.
HIv infected patients, visiting the outpatient clinic in cologne in a predefined time period and generally suitable for an active
immunization, were offered a pandemic influenza vaccination. If rejected, reasons for the refusal were recorded with the help of
the preset answers 1-8. (total n = 136)
1. Fätkenheuer_Umbruchvorlage  12.07.11  11:29  Seite 292(Study 113630, nct00975884; http://download.gsk-
clinicalstudyregister.com/files/28342.pdf; last accessed
September  20,  2010).  the  subjects  included  162
healthy adults aged 18 to 60.
compared to a matched subset within our tolera-
bility Study group (limited to those at age 18-60 years,
n = 423), gSK-study participants had a similar mean
age (40 years vs. 43 years in HIv-infected patients) and
gender allocation was more balanced (47% male par-
ticipants in the gSK study vs. 81% men in our HIv
cohort).
the following differences regarding occurrence of
symptoms 7 days after the application of the first dose
of Pandemrixﾮ are apparent. Pain at the injection site
was reported much less frequently in our study than in
the gSK study (261/423 (62%) vs. 154/162 (95%)).
on the other hand, HIv-patients in our study reported
fever (defined as ≥38.0 ﾰc) more often (46/423 pa-
tients;  11%)  than  participants  in  the  gSK  study
(3/162; 2%, fever defined as ≥37.5ﾰc).
As injection site reactions such as pain are most of-
ten caused by local immune reactions, impaired reac-
tiveness of the immune system to vaccinations due to
HIv infection might explain the lower number of lo-
cal symptoms observed in our study group.  the fact
that symptoms within the HIv+ cohort occurred irre-
spective of cd4-count might correspond to an im-
paired immune capacity not reflected by cd4-count
alone. the reasons for the higher rates of fever ob-
served in our HIv-cohort remain unclear at that point.
While this study did not investigate on the effective-
ness  of  the  vaccination,  several  studies  on  the  im-
munogenicity of pandemic influenza vaccines in HIv
patients are available [16-20].
At  the  same  time,  data  on  the  tolerability  of  an
AS03-adjuvanted vaccine in HIv-infected patients has
only been shown by tREMBlAy et al. for a smaller
group  of  participants  (n=84)  [20].  Results  are  in  a
comparable range to the results in this study. Active
immunization with the AS03 adjuvant appears to be
safe and well tolerated in HIv-infected patients.
concluSIon
A total of 622 HIv-infected patients were vaccinated
against nH1n1-Influenza using adjuvantated vaccine.
no severe adverse events were reported. the vaccine
was well tolerated. Rates of side effects were similar to
those seen in comparable studies with HIv-negative
participants. Acceptance rate of influenza vaccination
was high among HIv-infected patients (75%). those
refusing the immunization mentioned negative media
coverage as the major influence on their decision
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